Hwail Pharm Co Ltd
KOSDAQ:061250
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Devyser Diagnostics AB
STO:DVYSR
|
SE |
|
I
|
Inox Green Energy Services Ltd
NSE:INOXGREEN
|
IN |
|
Zhaoke Ophthalmology Ltd
HKEX:6622
|
CN |
|
Highwoods Properties Inc
NYSE:HIW
|
US |
|
C
|
Chengdu Bright Eye Hospital Co Ltd
SZSE:301239
|
CN |
|
E
|
Enel Chile SA
SGO:ENELCHILE
|
CL |
Hwail Pharm Co Ltd
Operating Expenses
Hwail Pharm Co Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hwail Pharm Co Ltd
KOSDAQ:061250
|
Operating Expenses
-₩8.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
Yuhan Corp
KRX:000100
|
Operating Expenses
-₩625.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Expenses
-₩459.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Expenses
-₩626.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Expenses
-₩100.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Operating Expenses
-₩31.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Hwail Pharm Co Ltd
Glance View
HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 149 full-time employees. The company went IPO on 2002-04-18. The firm produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Hwail Pharm Co Ltd's Operating Expenses?
Operating Expenses
-8.9B
KRW
Based on the financial report for Dec 31, 2025, Hwail Pharm Co Ltd's Operating Expenses amounts to -8.9B KRW.
What is Hwail Pharm Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-1%
Over the last year, the Operating Expenses growth was 9%. The average annual Operating Expenses growth rates for Hwail Pharm Co Ltd have been -1% over the past three years , 3% over the past five years , and -1% over the past ten years .
